Key Takeaways
- • Ropes & Gray advised Bain Capital Private Equity on a USD 600 million Series B financing for Kailera Therapeutics, marking Bain Capital's inaugural investment in the obesity treatment biotech company.
- • The financing will fund global Phase 3 clinical trials of KAI-9531, Kailera's lead candidate, a dual GLP-1/GIP receptor agonist injectable that has demonstrated encouraging results in Chinese clinical studies.
- • The deal attracted a broad consortium of institutional investors including Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Surveyor Capital (Citadel), and T. Rowe Price Associates.
- • Kailera Therapeutics, based in Waltham, Massachusetts and San Diego, California, is developing a diversified pipeline of injectable and oral obesity treatment therapies across multiple mechanisms of action and delivery routes.
- • The financing is fully committed at closing, representing significant institutional validation for the obesity treatment sector and Bain Capital's expansion into biotech venture-scale investments.
Summary
Global law firm Ropes & Gray has guided Bain Capital Private Equity through a USD 600 million Series B financing round for Kailera Therapeutics, a biotechnology company focused on developing next-generation obesity treatment therapies. This investment marks Bain Capital Private Equity's inaugural biotech investment in Kailera, signaling the firm's strategic pivot toward the high-growth obesity treatment market.
Kailera Therapeutics, headquartered across Waltham, Massachusetts and San Diego, California, specializes in developing injectable and oral formulations for obesity treatment. The company is building a broad portfolio of therapies with differentiated mechanisms of action and multiple delivery routes. The Series B proceeds will primarily support advancement of KAI-9531, the company's most advanced program—a dual GLP-1/GIP receptor agonist administered via injection that has generated encouraging results in clinical trials conducted in China. The financing will specifically fund global Phase 3 clinical trial expansion for this candidate.
The Ropes & Gray advisory team was led by private equity partner Bill Mone, venture capital and emerging companies partner Rajarshi Banerjee, and counsel Michael Connolly. The firm mobilized cross-functional expertise spanning intellectual property transactions, asset management, antitrust, employment, executive compensation and benefits, life sciences, strategic transactions, data and privacy/cybersecurity practices—reflecting the regulatory and operational complexity of biotech financing structures.
The financing attracted substantial institutional participation beyond Bain Capital, with investors including Adage Capital Management LP, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (QIA), Royalty Pharma, Surveyor Capital (a Citadel company), and T. Rowe Price Associates. The round is fully funded at closing, reflecting strong institutional confidence in obesity treatment development pipelines and Kailera's clinical progress to date.
Kailera Therapeutics, headquartered across Waltham, Massachusetts and San Diego, California, specializes in developing injectable and oral formulations for obesity treatment. The company is building a broad portfolio of therapies with differentiated mechanisms of action and multiple delivery routes. The Series B proceeds will primarily support advancement of KAI-9531, the company's most advanced program—a dual GLP-1/GIP receptor agonist administered via injection that has generated encouraging results in clinical trials conducted in China. The financing will specifically fund global Phase 3 clinical trial expansion for this candidate.
The Ropes & Gray advisory team was led by private equity partner Bill Mone, venture capital and emerging companies partner Rajarshi Banerjee, and counsel Michael Connolly. The firm mobilized cross-functional expertise spanning intellectual property transactions, asset management, antitrust, employment, executive compensation and benefits, life sciences, strategic transactions, data and privacy/cybersecurity practices—reflecting the regulatory and operational complexity of biotech financing structures.
The financing attracted substantial institutional participation beyond Bain Capital, with investors including Adage Capital Management LP, Canada Pension Plan Investment Board (CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority (QIA), Royalty Pharma, Surveyor Capital (a Citadel company), and T. Rowe Price Associates. The round is fully funded at closing, reflecting strong institutional confidence in obesity treatment development pipelines and Kailera's clinical progress to date.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.